Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01183949 · ClinicalTrials.gov registry record · Phase 1
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
A Phase 1 study of Multiple Myeloma, sponsored by Astex Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 5
- Study locations
NCT01183949 is a Phase 1 study of Multiple Myeloma that has completed, run by Astex Pharmaceuticals. The registered enrollment target is 18 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 3 states.
The verdict
NCT01183949, a Phase 1 study of Multiple Myeloma, has completed, sponsored by Astex Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to determine whether AT7519M alone or AT7519M plus bortezomib are effective treatments in patients with previously treated multiple myeloma.
Conditions Studied
Interventions
- DRUG Bortezomib
- DRUG AT7519M
Study Locations (5)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Massachusetts General Hospital - Boston
- Dana Faber Cancer Institute - Boston
New York
- Memorial Sloan-Kettering Cancer Centre - New York
Wisconsin
- MCW and Froedtert Clinical Cancer Center, Division of Neoplastic Diseases & Related Disorders - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2010-11 |
| Est. Completion | 2015-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01183949
The ClinicalTrials.gov registry entry for NCT01183949 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (97% lower). The listed sponsor is Astex Pharmaceuticals, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Bortezomib is the first listed.
NCT01183949 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, New York, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT01183949 about?
NCT01183949 is a clinical study titled "Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma". The purpose of this study is to determine whether AT7519M alone or AT7519M plus bortezomib are effective treatments in patients with previously treated multiple myeloma.
What is the current status of trial NCT01183949?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2010-11. Estimated completion is 2015-03.
What conditions does trial NCT01183949 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT01183949?
The interventions under investigation include: Bortezomib (DRUG), AT7519M (DRUG).
Who is sponsoring clinical trial NCT01183949?
This trial is sponsored by Astex Pharmaceuticals, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01183949 being conducted?
This trial has 5 study locations across Massachusetts, New York, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.